Nicole S. Verkaik

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Motion-based tissue ex vivo (MOTEX) assay to assess proton and X-ray irradiation responses in head and neck squamous cell carcinoma.

Motion-based tissue ex vivo (MOTEX) assay to assess proton and X-ray irradiation responses in head and neck squamous cell carcinoma.

Journal: Clinical and translational radiation oncology
Published: September 25, 2025

Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses.

Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses.

Journal: EJNMMI research
Published: August 06, 2025

Motion based ex vivo (MOTEX) culture of breast tumor slices sustains microenvironment composition.

Motion based ex vivo (MOTEX) culture of breast tumor slices sustains microenvironment composition.

Journal: Neoplasia (New York, N.Y.)
Published: July 14, 2025

Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells.

Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells.

Journal: Cancers
Published: June 02, 2025

Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay.

Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay.

Journal: NPJ breast cancer
Published: August 07, 2024

Development of an Ex Vivo Functional Assay for Prediction of Irradiation Related Toxicity in Healthy Oral Mucosa Tissue.

Development of an Ex Vivo Functional Assay for Prediction of Irradiation Related Toxicity in Healthy Oral Mucosa Tissue.

Journal: International journal of molecular sciences
Published: May 13, 2024

Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.

Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.

Journal: Cancers
Published: November 24, 2023

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo.

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo.

Journal: Theranostics
Published: January 27, 2023

Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients.

Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients.

Journal: NPJ breast cancer
Published: January 19, 2023

In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib.

In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib.

Journal: Cancers
Published: January 11, 2023

Ex Vivo Functional Assay for Evaluating Treatment Response in Tumor Tissue of Head and Neck Squamous Cell Carcinoma.

Ex Vivo Functional Assay for Evaluating Treatment Response in Tumor Tissue of Head and Neck Squamous Cell Carcinoma.

Journal: Cancers
Published: November 30, 2022

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.

Journal: International journal of molecular sciences
Published: June 17, 2022
Showing 1-12 of 28

Last Updated: 09/26/2026